Contact us Demo our platform

COVID-19

Rapidly Unlocking Actionable Insights in the Fight Against COVID-19

How we are making a difference today

Metabolon has made quick connections with several leading medical centers and heads of large cohorts to leverage the power of our metabolomics platform and gain deep insights into all aspects of the COVID-19 pandemic.

Current COVID-19 projects include:

  • High-throughput global and lipidomic analysis of serially collected samples from hospitalized ICU patients to provide a comprehensive view of metabolic perturbations associated with patient disease responses and identify biomarkers specific for each stage of infection
  • Global metabolomic profiling of longitudinal plasma samples from confirmed COVID-positive patients to understand system metabolic changes over the trajectory of infection and which patients are at the highest risk of severe infection
  • Metabolomic profiling to better understand COVID vaccine development and efficacy, including (1) responses to immunization for early detection and even prediction of potential adverse events, (2) protective effects of immunization against infection and disease: that leverages metabolomics to monitor response to immunization, and (3) guidelines for basic research to identify metabolites characteristic for prevention of disease by vaccination
  • Global metabolomic profiling to probe host immune responses to SARS-CoV-2 during asymptomatic and symptomatic phases of infection to identify biomarkers that predict disease severity in vulnerable populations
  • Global metabolomic and lipidomic profiling to identify at-risk individuals for COVID infection and stratify populations for potential treatment options
  • Interventional clinical trial to assess the effectiveness of hydroxychloroquine as a treatment for COVID-19. This same approach can be deployed to understand the effectiveness of all other therapeutics, such as remdesivir
  • Direct comparison of baseline versus infected samples in patients who were subsequently confirmed positive for COVID to discover markers of infection and why individuals display large differences in infection severity

Contact us today for free study-design consultation with our infectious-disease experts.

Learn more about how metabolomics provides a comprehensive view for more informed decisions

Comprehensive metabolomic profiling can simultaneously inform on several biological processes relevant to infection, such as inflammatory and redox markers, energetics, microbiome contribution, and xenobiotic impact. These insights can lead to predictive response signatures and therapy strategies.

The following publications exemplify how metabolomics can provide unique biological insights supporting infectious disease and countermeasures research:

Publications

Predicting COVID-19 disease severity

  • Integration of metabolomics and proteomics to develop a predictive model (Shen, B, Cell, 2020; PMID: 32492406)

Pathophysiology and Immune Response

Optimization of vaccine production and therapeutic development

Patient stratification and risk assessment

Metabolomic profiling for the identification of therapeutics for viral infections

Case Studies

  • Pathophysiology and Immune Response – Understanding the pathophysiology and immune response of infectious diseases is vital for discovering effective treatments. These case studies support several problem-oriented metabolomics applications to SARS-CoV-2 by identifying metabolomic changes during infection and predicting disease severity and need for effective intervention and efficacy.
  • Optimization of vaccine production and therapeutic development – When dealing with a pandemic like COVID-19, vaccine development and discovery of therapeutics are essential to improving outcomes. These case studies address the need for actionable insights for vaccine development that metabolomics provides through a comprehensive view driving operational and quality improvements and antibody production.
  • Patient stratification and risk assessment – Understanding the effects of age, gender and comorbidities on susceptibility to COVID-19, response to treatment and outcomes like mortality are vital for improved outcomes. These case studies highlight how metabolomics guides effective intervention and efficacy.
  • Metabolomic profiling for identification of therapeutics for viral infections – Comprehensive metabolomic profiling can simultaneously inform on several biological processes relevant to infection, such as inflammatory and redox markers, energetics, microbiome contribution and xenobiotic impact. These insights can lead to predictive response signatures and therapy strategies. The following case studies demonstrate how metabolomics enhances understanding of viral activity, helps to predict viral treatment and supports informed decisions on vaccine development.

Science Goes On: Join our Conversation

Metabolon understands that science goes on no matter the circumstances. That’s why we’re proud to introduce Insights & Discoveries with Metabolon, a virtual event series to continue the conversation around the science of life. We’ve assembled our team of experts along with guest speakers for some events to discuss scientific advances in metabolomics that are driving research forward.

For more information or to sign up for notifications on the series, click here.

More COVID-19 Information

See how Metabolon can advance your path to preclinical and clinical insights

Get A Project Quote

Contact Us

Talk with an expert

Request a quote for our services or more information on sample types and handling procedures, need a letter of support, or simply have questions about how metabolomics can advance your research.

Corporate Headquarters

617 Davis Drive, Suite 100
Morrisville, NC 27560

Mailing Address:
P.O. Box 110407
Research Triangle Park, NC 27709

+1 (919) 572-1711

+1 (919) 572-1721

International Headquarters

Metabolon GmbH

Zeppelinstraße 3
85399 Hallbergmoos
Germany

+49 89 99017752
✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.